Role of serum TGF-β1 level in atrial fibrosis and outcome after catheter ablation for paroxysmal atrial fibrillation

Abstract This study aimed to evaluate the relationship between serum transforming growth factor-&bgr;1 (TGF-&bgr;1) concentration and atrial fibrosis and to determine whether plasma TGF-&bgr;1 concentration is an independent predictor of atrial fibrillation (AF) recurrence after catheter ablation. We included 98 consecutive patients who underwent catheter ablation, including 38 with paroxysmal AF (AF group) and 60 with paroxysmal supraventricular tachycardia (control group). We compared their preablation serum concentration of biomarkers and clinical and echocardiographic findings. Serum TGF-&bgr;1 concentrations, type-III procollagen N-terminal peptides (PIIINP), type-IV procollagen (IV-C), and laminin (LN) were significantly higher in the AF group than in the control group; however, there was no correlation between their concentrations and left atrial diameter (LAD). The area of the low-voltage zone positively correlated with TGF-&bgr;1 and PIIINP concentrations, but not with LAD. Atrial tachyarrhythmia (AF and AFL/AT) recurrence was observed in 15 patients (39.4%) at mean 241.4 ± 68.5 days of follow-up 12 months after ablation. Regression analysis revealed that TGF-&bgr;1 was a major risk factor for AF recurrence (odds ratio, 1.14; 95% confidence interval, 1.11–1.17; P = .02). Serum TGF-&bgr;1 concentration is an independent predictor of AF recurrence in patients with paroxysmal AF and may help identify patients likely to have better outcomes after catheter ablation.

[1]  Yinglong Hou,et al.  Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  S. Po,et al.  Vagal response during pulmonary vein isolation: Re-recognized its characteristics and implications in lone paroxysmal atrial fibrillation. , 2016, International journal of cardiology.

[3]  I. Erden,et al.  Predictors of atrial fibrillation recurrence after cryoballoon ablation , 2015, Journal of blood medicine.

[4]  Liang-ping Zhao,et al.  Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. , 2014, European heart journal.

[5]  J. Olgin,et al.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. , 2013, Cardiovascular research.

[6]  Yong Li,et al.  Increased Expression of Connective Tissue Growth Factor and Transforming Growth Factor-Beta-1 in Atrial Myocardium of Patients with Chronic Atrial Fibrillation , 2013, Cardiology.

[7]  T. Chao,et al.  Transforming growth factor-β1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. , 2013, Heart rhythm.

[8]  T. Chao,et al.  A Novel Finding of the Atrial Substrate Properties and Long‐Term Results of Catheter Ablation in Chronic Atrial Fibrillation Patients with Left Atrial Spontaneous Echo Contrast , 2012, Journal of cardiovascular electrophysiology.

[9]  H. Pak,et al.  High plasma concentrations of transforming growth factor-β and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[10]  Tadashi Fujino,et al.  Clinical Characteristics of Patients With Persistent Atrial Fibrillation Successfully Treated by Left Atrial Ablation , 2010, Circulation. Arrhythmia and electrophysiology.

[11]  H. Lei,et al.  TGF‐β1 Expression and Atrial Myocardium Fibrosis Increase in Atrial Fibrillation Secondary to Rheumatic Heart Disease , 2010, Clinical cardiology.

[12]  David O. Martin,et al.  Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. , 2009, Heart rhythm.

[13]  Y. On,et al.  Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. , 2009, The Journal of thoracic and cardiovascular surgery.

[14]  F. Sacher,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.

[15]  B. Gersh,et al.  Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[16]  F. Sacher,et al.  Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Long-term clinical outcome. , 2007, European heart journal.

[17]  David Tamborero,et al.  Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. , 2007, European heart journal.

[18]  James B Seward,et al.  Left atrial size: physiologic determinants and clinical applications. , 2006, Journal of the American College of Cardiology.

[19]  R. Sheppard,et al.  Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.

[20]  P. Collinson,et al.  Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: Implication for diagnosis of diastolic heart failure , 2006, European journal of heart failure.

[21]  Sander Verheule,et al.  Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.